UroGen Pharma Ltd. (FRA:UR8)
Germany
· Delayed Price · Currency is EUR 20.40
0.00 (0.00%)
At close: Dec 5, 2025
UroGen Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -164.64 | -126.87 | -102.24 | -109.78 | -110.82 | -128.48 | Upgrade
|
| Depreciation & Amortization | 2.04 | 1.19 | 1.71 | 1.82 | 1.77 | 2.04 | Upgrade
|
| Other Amortization | - | - | - | 1.75 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -3.14 | -2.89 | -1.03 | -0.5 | 0.48 | 0.44 | Upgrade
|
| Stock-Based Compensation | 12.13 | 13.11 | 9.34 | 10.58 | 23.11 | 28.03 | Upgrade
|
| Other Operating Activities | 11.19 | 13.77 | 12.52 | 13.75 | 13.67 | -1.54 | Upgrade
|
| Change in Accounts Receivable | 3.1 | -4.86 | -2.74 | -0.99 | -4.67 | -7.05 | Upgrade
|
| Change in Inventory | -0.75 | -3.55 | -1.35 | -0.36 | -2.87 | -1.96 | Upgrade
|
| Change in Accounts Payable | 6.49 | 10.89 | 4.16 | 0.28 | 2 | -1.25 | Upgrade
|
| Change in Income Taxes | 0.6 | 0.6 | 0.18 | 0.18 | 0.13 | 2.72 | Upgrade
|
| Change in Other Net Operating Assets | -4.76 | 1.86 | 3.09 | -4.29 | -7.69 | 1.17 | Upgrade
|
| Operating Cash Flow | -137.74 | -96.77 | -76.38 | -87.56 | -84.89 | -105.89 | Upgrade
|
| Capital Expenditures | -0.39 | -0.3 | -0.19 | -0.25 | -0.75 | -1.22 | Upgrade
|
| Investment in Securities | 94.85 | -20.32 | -0.76 | 1.31 | 4.82 | 94.45 | Upgrade
|
| Investing Cash Flow | 94.46 | -20.61 | -0.95 | 1.06 | 4.07 | 93.24 | Upgrade
|
| Long-Term Debt Issued | - | 24.49 | - | 95.78 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | - | 24.49 | - | 95.78 | - | - | Upgrade
|
| Issuance of Common Stock | 8.67 | 151.49 | 68.23 | 1.51 | 72.46 | 16.59 | Upgrade
|
| Other Financing Activities | 0 | 18.64 | 48.7 | -0.16 | -0.14 | -0.07 | Upgrade
|
| Financing Cash Flow | 8.67 | 194.62 | 116.93 | 97.13 | 72.32 | 16.53 | Upgrade
|
| Net Cash Flow | -34.6 | 77.24 | 39.6 | 10.64 | -8.5 | 3.88 | Upgrade
|
| Free Cash Flow | -138.13 | -97.06 | -76.57 | -87.81 | -85.64 | -107.1 | Upgrade
|
| Free Cash Flow Margin | -143.11% | -107.37% | -92.57% | -136.45% | -178.27% | -907.71% | Upgrade
|
| Free Cash Flow Per Share | -2.90 | -2.26 | -2.66 | -3.85 | -3.83 | -4.92 | Upgrade
|
| Levered Free Cash Flow | -65.87 | -46.83 | -35.16 | -42.79 | -44.14 | -55.94 | Upgrade
|
| Unlevered Free Cash Flow | -56.21 | -39.01 | -25.96 | -39.27 | -44.14 | -55.94 | Upgrade
|
| Change in Working Capital | 4.68 | 4.93 | 3.34 | -5.18 | -13.11 | -6.37 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.